NASDAQ:PRAX Praxis Precision Medicines Q1 2025 Earnings Report $280.78 -1.01 (-0.36%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$279.12 -1.66 (-0.59%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Praxis Precision Medicines EPS ResultsActual EPS-$3.29Consensus EPS -$3.20Beat/MissMissed by -$0.09One Year Ago EPSN/APraxis Precision Medicines Revenue ResultsActual RevenueN/AExpected Revenue$0.20 millionBeat/MissN/AYoY Revenue GrowthN/APraxis Precision Medicines Announcement DetailsQuarterQ1 2025Date5/2/2025TimeBefore Market OpensConference Call DateFriday, May 2, 2025Conference Call Time8:30AM ETUpcoming EarningsPraxis Precision Medicines' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Praxis Precision Medicines Earnings HeadlinesPraxis Precision Medicines (NASDAQ:PRAX) Earns Buy Rating from Needham & Company LLCSeptember 26 at 1:54 AM | americanbankingnews.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Average Recommendation of "Moderate Buy" from AnalystsSeptember 21, 2026 | americanbankingnews.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.September 27 at 1:00 AM | Altimetry (Ad)Praxis Precision Medicines Inc (PRAX)September 19, 2026 | in.investing.comPraxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade)September 12, 2026 | seekingalpha.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3, 2026 | globenewswire.comSee More Praxis Precision Medicines Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Praxis Precision Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Praxis Precision Medicines and other key companies, straight to your email. Email Address About Praxis Precision MedicinesPraxis Precision Medicines (NASDAQ:PRAX) (NASDAQ: PRAX) is a biotechnology company focused on developing treatments for central nervous system disorders, including epilepsy, movement disorders and other neurological conditions. The company uses its Precision Genetic Medicine platform, which combines human genetics, functional genomics and neuroscience research to identify disease mechanisms and potential therapeutic targets. Praxis’ pipeline has included investigational medicines such as ulixacaltamide, a treatment candidate being developed for essential tremor, and elsunersen, an antisense oligonucleotide designed for certain severe genetic epilepsies. The company has also evaluated PRAX-628, a next-generation sodium-channel modulator for seizure disorders. These programs are intended to address neurological diseases with significant unmet medical needs. Founded in 2015 and headquartered in Boston, Massachusetts, Praxis conducts research and clinical development activities through collaborations and studies involving patients in multiple regions. The company is led by President and Chief Executive Officer Marcio Souza.View Praxis Precision Medicines ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/252 Cybersecurity Stocks Breaking Out as AI Continues to Be a TailwindCostco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem5 Scary-Good Stocks With Strong October Catalysts and Breakout PotentialDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
